CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Study title/design: A study to evaluate the efficacy and safety of oral zavegepant in migraine prevention (NCT04804033) Trial NCT04804033. Estimated completion December 15 2027 Aim To compare the efficacy of zavegepant (BHV-3500) to placebo as a preventive treatment for migraine, as measured by reduction in number of migraine days per month (MMD). Study design Phase …
Read more »Study title/design: Long term safety study of zavegepant (BHV-3500) for the acute treatment of migraine (NCT04408794) Trial NCT04408794. Completed December 23 2021 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, open-label, …
Read more »Study title/design: Acute treatment trial of zavegepant (BHV-3500) in adults with migraine (NCT03872453) Trial NCT03872453. Completed November 11 2019 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, double-blind, randomised, placebo-controlled, dose-ranging …
Read more »Study title/design: Randomised trial of zavegepant (BHV-3500) in adults with acute migraine (NCT04571060) Trial NCT04571060. Completed October 22 2021 Aim To test the safety and efficacy of zavegepant (BHV-3500) versus placebo, in the acute treatment of moderate to severe migraine. Study design Phase 3, double-blind, randomised, placebo-controlled, safety and efficacy trial of intranasal zavegepant 10 …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
